EDGAR Filing Documents for 0001193125-20-148659

Form 8-K - Current report:

SEC Accession No. 0001193125-20-148659

Filing Date

2020-05-21

Accepted

2020-05-21 16:06:11

Documents

Period of Report

2020-05-18

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d934830d8k.htm iXBRL	8-K	39946
2	EX-1.1	d934830dex11.htm	EX-1.1	188894
3	EX-5.1	d934830dex51.htm	EX-5.1	9950
4	EX-99.1	d934830dex991.htm	EX-99.1	10117
5	EX-99.2	d934830dex992.htm	EX-99.2	9591
9	GRAPHIC	g934830g03j75.jpg	GRAPHIC	5198
10	GRAPHIC	g934830image3.jpg	GRAPHIC	11149
	Complete submission text file	0001193125-20-148659.txt		466112

Data Files

Seq	Description	Document	Type	Size
6	XBRL TAXONOMY EXTENSION SCHEMA	clvs-20200518.xsd	EX-101.SCH	3088
7	XBRL TAXONOMY EXTENSION LABEL LINKBASE	clvs-20200518_lab.xml	EX-101.LAB	18139
8	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	clvs-20200518_pre.xml	EX-101.PRE	11420
13	EXTRACTED XBRL INSTANCE DOCUMENT	d934830d8k_htm.xml	XML	3356

Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301

Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000

Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)